VR Adviser Adds Over 1 Million Savara Shares
2026-03-15 10:59:05 ET
According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara (NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued at $82.9 million.
Savara is a clinical-stage biotechnology company specializing developing inhaled biologics for rare respiratory diseases. The company leverages its expertise in respiratory drug delivery to address significant unmet medical needs, with molgramostim as its lead product in late-stage clinical trials. With a focused pipeline and a targeted approach to rare disease markets, Savara aims to establish a competitive position in the orphan drug segment of the healthcare industry.
VR Adviser upped its stake in Savara’s stock, already a significant portion of its assets under management (AUM), by over 1 million shares. The firm owned 13.7 million shares valued at $82.9 million as of Dec. 31.
NASDAQ: SYRE
SYRE Trading
2.24% G/L:
$44.435 Last:
135,308 Volume:
$44.25 Open:
